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Prolonged Signal-Averaged P-Wave Duration as an
Intermediate Phenotype for Familial Atrial Fibrillation
Dawood Darbar, MD, FACC,* Amanda Hardy, RN,* Jonathan L. Haines, PHD,†
Dan M. Roden, MD, FACC‡
Nashville, Tennessee
Objectives This study sought to perform a genome-wide linkage analysis in a large atrial fibrillation (AF) kindred using AF
and abnormally prolonged signal-averaged (SA) P-wave duration as the phenotype.
Background Although inherited forms of AF exist, phenotypic complexity has limited efforts to ascertain mutation carriers
and thus identify causal genes. The identification of intermediate or endophenotypes may accelerate this effort.
Methods A genome-wide linkage analysis was performed in a 4-generation AF kindred of 27 individuals, 8 with AF docu-
mented by electrocardiogram. The analysis was performed using AF as the phenotype, and repeated using an
abnormally prolonged SA P-wave duration as the phenotype.
Results Linkage analysis and fine mapping generated a maximum multipoint logarithm of the odds (LOD) score of 3.0 at
chromosome 5p15 between markers D5S406 and D5S635. Importantly, 8 heterozygous carriers had a pro-
longed SA P-wave (203  21 ms) compared with 17 noncarriers (116  12 ms, p  0.00001). Using prolonged
SA P-wave (conventionally defined as 155 ms) as an endophenotype, a maximum LOD score of 3.6 was ob-
tained in the same region of chromosome 5p15, a span of 5.75 centi-Morgans.
Conclusions In a large AF kindred, we have identified a novel AF locus on chromosome 5p15 and shown that affected indi-
viduals with AF and mutation carriers can be identified by a prolonged SA P-wave duration. Importantly, identifi-
cation of an endophenotype in this kindred not only aided ascertainment of additional family members but also
increased the LOD score, providing increased support for linkage at this locus. Identification of the causal gene,
mapped to chromosome 5p15, will advance our understanding of the molecular basis of AF. (J Am Coll Cardiol
2008;51:1083–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.058l
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otrial fibrillation (AF), the most common cardiac arrhyth-
ia, affects approximately 2 million Americans (1) and
esults in substantial morbidity and mortality (2). Atrial
brillation is also the most common arrhythmia requiring
rug therapy, and the limited success of drug therapy for AF
ay in part reflect poor understanding of its diverse molec-
lar underlying pathophysiology. Recent studies have pro-
ided evidence of a genetic contribution to AF (3,4).
utations in potassium-channel genes have been associated
ith familial AF but account for only a small fraction of all
ases of AF (5–9). In addition, a number of loci that confer
ncreased vulnerability to AF have been described (9,10).
lthough Mendelian forms of AF are not rare (3), large
indreds such as those used to identify disease genes in
ther inherited arrhythmia syndromes, such as congenital
rom the *Department of Medicine, †Center for Human Genetics Research, and
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville,
ennessee. This work was supported by National Institutes of Health grant
L075266 to Dr. Darbar and UO1 HL65962 to Dr. Roden.f
Manuscript received July 23, 2007; revised manuscript received November 12,
007, accepted November 12, 2007.ong QT syndrome (11,12), are unusual. One possible
eason for such complexity is reduced penetrance with less
pparent heritability, and thus a smaller genetic contribu-
ion to the ultimate clinical phenotype. Another possible
echanism is that the phenotype may be the result of
nteraction of several genes, that is, polygenic, each with a
mall overall contribution. Finally, AF may require addi-
ional environmental events to reduce the AF threshold
ufficiently to trigger an episode of AF (13).
See page 1090
The paroxysmal nature and variable symptoms in AF, a
igh prevalence in the general population, and a late age of
nset in many individuals all make assignment of the clinical
henotype challenging. A number of strategies can be
sed to minimize misphenotyping, including affected-
ndividuals-only analysis and diagnosis by offspring, all of
hich reduce the power and maximum logarithm of the
dds (LOD) score. This complexity has compelled a search
or new, more effective methods for investigating the genet-
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Prolonged P-Wave and Familial AF March 18, 2008:1083–9ics of complex diseases such as
AF (14). One approach is to use
the families of affected individu-
als as an enriched target popula-
tion for the definition and eval-
uation of novel phenotypes. The
psychiatric field has pioneered
systematic approaches to pheno-
typing in an attempt to discover
ntermediate or endophenotypes, that is, subtle or novel
henotypes that are causally related to the poorly penetrant
lassical clinical syndromes (15). One such example is
mpaired attention, which has proved useful for genetic
tudies of schizophrenia (16). In the case of AF, examples of
otential endophenotypes include signal-averaged (SA)
-wave duration, pulmonary venous anatomy as assessed by
omputed tomography or magnetic resonance imaging, and
rofiles of biomarkers (17,18). If such markers of a reduced
hreshold for AF can be defined, then not only will they be
linically useful (e.g., to categorize subsets of patients with AF),
ut they will also accelerate the identification of causal genes.
Signal-averaged P-wave electrocardiograms (ECGs) have
een shown to have a potential role in identifying patients at
isk of developing paroxysmal AF and those likely to
rogress from paroxysmal AF to chronic AF (19). The SA
-wave ECG measures delayed potentials indicative of
elayed intra-atrial and interatrial conduction. Because con-
uction delays are critical for the initiation of re-entrant
rrhythmias, evidence of a prolonged P-wave duration using
ignal-averaging techniques provides a means by which
atients at risk of developing AF can be identified. In this
tudy, we describe the identification of a novel locus for familial
F that is inherited in an autosomal-dominant manner. In
ddition, we show that affected individuals with AF can be
dentified by a prolonged SA P-wave, whereas noncarriers have
ormal P-wave duration, supporting a primary defect in atrial
ctivation as the cause of AF in this kindred.
ethods
linical evaluations. All studies were performed with the
pproval of the Institutional Review Board of Vanderbilt
niversity Medical Center. Each family member had a
hysical examination and gave a detailed history to identify
ast medical conditions, symptoms while in AF, and the
edical history of first-degree relatives. Each subject was
valuated by 12-lead ECG, echocardiogram, P-wave SA
CG, and laboratory studies including thyroid-stimulating
ormone.
The proband and relatives were clinically classified using
consistently applied set of definitions. The AF was defined
s replacement of sinus P waves by rapid oscillations or
brillatory waves that varied in size, shape, and timing and
ere associated with an irregular ventricular response when
Abbreviations
and Acronyms
AF  atrial fibrillation
ECG  electrocardiogram
LOD  logarithm of the
odds
SA  signal-averagedtrioventricular conduction was intact. Documentation of MF on an ECG, rhythm strip, event, or Holter monitor was
equired. Lone AF was defined as AF in individuals 60
ears of age without hypertension or overt structural heart
isease by clinical examination, ECG, and echocardiogra-
hy. The upper limits of normal for cardiac chamber
imensions were based on age and body surface area (20).
e defined as affected those individuals with ECG-
ocumented AF. We defined as unaffected only those
ndividuals 60 years of age with no personal history of AF
nd no offspring with a history of AF. All other family
embers were defined as unknown for the purpose of initial
enetic analyses.
ignal-averaged P-wave duration. All subjects were in
inus rhythm at the time of the SA P-wave recording. In
ddition, all cardioactive drugs, including antiarrhythmic
rugs, were withdrawn for at least 5 half-lives before the
ecordings were performed. The methodology of SA
-wave duration recording and analysis has been described
reviously (19,21). This was recorded using the MAC 5000
GE Medical Systems, Milwaukee, Wisconsin). In brief,
he SA P-wave duration was obtained from a relaxed patient
n a supine position in a quiet room, free from electrical
nterference. It incorporates 3 bipolar orthogonal leads
eferred to as the X, Y, and Z leads, which correspond to
hose used for the acquisition of the standard ECG. The
ignal from each lead was amplified to 5 V/cm, passed
hrough a low-bandpass filter of 300 Hz and a high-
andpass filter of 40 Hz, and then converted from analog-
o-digital data to a 12-bit accuracy at the sampling rate of 1
Hz. A specially filtered P-wave derived from the selected
ominant sinus P-wave of lead II served as a reference signal
or all processing. After passing through a P-wave recogni-
ion program to eliminate ectopic atrial beats, 200 beats
ere averaged on a trigger point within the specially filtered
-wave. If the noise level remained 0.5 V, even after
00-beat averaging, the averaging was continued until the
eak noise was reduced to 0.5 V. The filtered signals for
he X, Y, and Z leads were combined into a vector
agnitude, the root mean square value. The filtered P-wave
uration in this vector was calculated. Previous studies
ave identified an abnormal SA P-wave filtered duration
s 155 ms (22).
enetic analyses. Whole blood for genomic deoxyribonu-
leic acid (DNA) extraction was obtained from the proband
nd all consenting family members. Genetic analyses were
erformed on all available individuals, regardless of affection
tatus. A genome-wide scan was performed by deCODE
Reykjavik, Iceland) using their 546-marker panel and
orresponding genetic map (23,24). These microsatellite
arkers span the human genome by every approximately 8
enti-Morgans (cM). Genotypes were ascertained without
nowledge of clinical status. Fine mapping was performed
t candidate loci using additional markers identified at the
enethon and Center for Medical Genetics, Marshfield
edical Research Foundation databases.
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March 18, 2008:1083–9 Prolonged P-Wave and Familial AFtatistical analyses. Two-point and multipoint LOD
cores were calculated assuming a disease penetrance of
.95. Allele frequencies were estimated from the population.
wo-point LOD scores were calculated with the MLINK
rogram (25,26). To estimate the most likely location for
isease, multipoint LOD scores were calculated using the
rogram SIMLINK (27,28). The parameters used for mul-
ipoint linkage analysis were identical to those for 2-point
inkage analysis. The distance (cM) between markers was
ased on the data from the Center for Medical Genetics,
arshfield Medical Research Foundation database. Data
or the SA P-wave duration are presented as the mean value
SD. Comparison of means was performed using the
tudent t-test.
esults
linical characteristics of the pedigree. In the 4-generation
amily, AF segregated as an autosomal-dominant trait
Fig. 1). The family originated from the middle Tennessee
egion of the U.S. In total 27 family members (18 male, 9
emale; ages from 12 to 70 years) were involved in the study,
6 of whom provided DNA samples. Nine family members
ad the diagnosis excluded as discussed above. One consan-
uineous marriage occurred in this family. There were 8
Figure 1 Pedigree and Haplotypes for Family VAF-1
Filled symbols indicate individuals with atrial fibrillation (AF), square or round dash
als. Proband is indicated by the arrow. Underlined numbers indicate unaffected in
ers D5S2088, D5S406, D52054, D5635, D5807, and D5S1486 below each indiv
haplotype. One consanguineous marriage is indicated by an equals sign. VAF  Vandividuals with documented AF on the ECG. Patient I:1
as coincidentally diagnosed with paroxysmal AF at the age
f 41 when her ECG was recorded for occupational reasons.
lthough the patient had noticed fatigue and decreased
xercise tolerance, these complaints had not prompted her
o see a physician. At the present time, Patient I:1 has
hronic AF that is managed with rate-control therapy.
atient I:2 was diagnosed with symptomatic paroxysmal AF
t the age of 45 years. He initially had a response to
ntiarrhythmic drugs, but gradually over the next decade his
F became drug resistant and he was placed on rate-control
herapy for chronic AF. Because he died at the age of 56,
robably of a cardiovascular cause, a DNA sample was not
vailable for this subject. The proband (II:18) developed
ymptoms of palpitations, lightheadedness, and dizziness at
he age of 32 but did not seek medical attention until he was
n his 40s. At the present time, he continues to have
ymptomatic paroxysmal AF that is adequately controlled
ith a combination of digoxin and beta-blockers.
In affected individuals, the mean age of onset of AF was
2  10 years (range 18 to 45 years). In this kindred AF
egan with paroxysmal episodes, but in 2 family members
I:1 and I:2) became chronic over time. The QT interval
as normal in all affected individuals. In most affected
bols indicate obligate carriers, and diagonal lines indicate deceased individu-
ls used in linkage analyses. Results of genotypic analysis are shown for mark-
The vertical black line to the left of some series of numbers indicates disease
ilt atrial fibrillation.ed sym
dividua
idual.
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Prolonged P-Wave and Familial AF March 18, 2008:1083–9ubjects, there was evidence of mild left atrial dilation and
o other evidence of structural heart disease. However,
chocardiography did reveal mild concentric left ventricular
ypertrophy in 2 subjects (II:16 and II:20). In both of these
ubjects, AF was diagnosed at least 2 years before treatment
or hypertension was initiated. No members of this kindred
ave undergone invasive electrophysiological evaluation.
inkage analysis. We identified preliminary evidence of
inkage with the marker D5S2054 (maximum LOD score
.4, theta  0) on chromosome 5p15. Additional markers,
ncluding D5S2088, D5S406, D5S635, D5S807, and
5S1486 were used for fine mapping. The peak multipoint
OD score of 3.0 was obtained for a region between
arkers D5S406 and D5S635. These results indicate that
he autosomal-dominant AF gene is located between markers
5S406 and D5S635, a region 5.75 cM in length (Fig. 2).
ignal-averaged P-wave duration. This was performed in
5 family members, including 8 family members with
ocumented AF and 17 individuals in whom the diagnosis
as ruled out. Because Patient I:1 was in chronic AF and I:2
as deceased, no SA P-wave duration was obtained in these
Figure 2 Ideogram of Chromosome 5 With Giemsa
Banding Patterns and Localization of the AF Locus
Genetic map with chromosome 5p15 markers;
location of putative AF gene is shown on the right. AF  atrial fibrillation.ndividuals. In individuals carrying the AF haplotype and eith a documented history of AF, the SA P-wave duration
as prolonged (Table 1) (Fig. 3). Importantly, 8 heterozy-
ous carriers had a prolonged SA P-wave (203  21 ms)
ompared with 17 noncarriers (116  12 ms, p  0.00001).
sing prolonged SA P-wave (conventionally defined as
155 ms [22]) as an endophenotype for AF, genome-wide
inkage was performed with 8 individuals classified as
ffected and 17 unaffected. We identified evidence of
inkage with the marker D5S2054 (maximum LOD score
.6, theta  0) in the same region of chromosome 5p15
Table 2). This LOD score is robust to changes in pen-
trance or allele frequency, and even analyses of affected
ndividuals only result in 2-point LOD scores of 2.8.
ecause this marker was fully informative, a multipoint
alculation achieved no higher LOD score. Although a
rolonged SA P-wave duration allowed us to improve the
OD score for this kindred, it did not narrow the region of
nterest.
iscussion
n this study, we have identified a novel locus for AF that is
apped to chromosome 5p15 and characterized by early
nset of AF. In addition, we have also shown that prolon-
ation of the SA P-wave duration cosegregates with AF and
eems to be an intermediate marker (endophenotype) for
dentifying individuals at increased risk for developing AF
n this kindred. Importantly, identification of an endophe-
otype not only aided ascertainment of additional family
embers but also increased the LOD score, providing
ncreased support for linkage at this locus. Identification of
he causal gene, mapped to chromosome 5p15, will not only
dvance our understanding of the molecular basis of AF but
ay also provide new therapeutic approaches to treat this
ommon and morbid condition.
The locus we have defined on chromosome 5p15
urrently extends over 5.75 cM. On the basis of the
ocations of the recombinant boundaries and the se-
uence of the human genome, the region includes 5
nnotated genes. One putative candidate gene is A
isintegrin-like and metalloprotease with thrombo-
pondin type 1 motif, 16 (ADAMTS-16) (29), whose
unctions include collagen processing as procollagen
-proteinase and cleavage of the matrix proteoglycans
ggrecan, as well as inhibition of angiogenesis and blood
oagulation homeostasis (30). However, we have been
nable to identify transcripts of this gene in a human
ardiac complementary DNA library. We have also per-
ormed direct DNA sequence analysis on the remaining 4
enes (LOC340094, FLJ33360, KIAA0947, and MED10)
n affected subjects II:10 and II:18 with unaffected II:22
s the control. However, no mutation was identified in
he coding and intron splice sequences of these genes.
Several lines of evidence raise the possibility that AF and
ome forms of dilated cardiomyopathy may be allelic. For
xample, this region of 5p is close to but does not overlap
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March 18, 2008:1083–9 Prolonged P-Wave and Familial AFith a previously reported locus for neonatal AF that is
ssociated with sudden death and variable cardiomyopathy
31). However, in our AF kindred, dilated cardiomyopathy
as not a feature of the clinical presentation. Support for
his has also recently come from identification of mutations
n the cardiac sodium channel (SCN5A) that manifest as
arly onset dilated cardiomyopathy and AF (32,33). The
loning of the causative genes at the 10q22, 6q14-16, and
p13 loci will further clarify the relationship between AF
nd cardiomyopathy (9,10,31).
tudy limitations. The genetic basis for the majority of
atients with AF remains unknown. Although familial AF
as been mapped to 3 other loci, identification of the
ausative genes has proved elusive. One possible reason
elates to phenotypic complexity of AF with the lack of a
iological basis for the classification of the disease. Others
nclude reduced penetrance of the gene and polygenic nature
linical Characteristics of Family Members
Table 1 Clinical Characteristics of Family Members
Pedigree Number
Age at
Evaluation
(yrs)
Age at
Onset
(yrs) Rhythm S
Affected and haplotype carriers
I:1 75 41 Chronic lone AF
I:2 Deceased NA Chronic AF
II:10 58 42 Paroxysmal AF
II:16 66 32 Paroxysmal AF
II:18 68 32 Paroxysmal
lone AF
II:20 70 30 Paroxysmal AF
III:1 38 18 Paroxysmal
lone AF
III:4 32 — NSR
III:6 34 18 Paroxysmal
lone AF
IV:1 22 — NSR
Unaffected
(individuals without
a disease haplotype)
II:1 52 — NSR
II:2 54 — NSR
II:3 57 — NSR
II:4 61 — NSR
II:5 64 — NSR
II:6 65 — NSR
II:7 67 — NSR
II:8 72 — NSR
II:9 55 — NSR
II:13 75 — NSR
II:14 72 — NSR
II:15 64 — NSR
II:21 63 — NSR
II:22 62 — NSR
III:2 60 — NSR
III:3 34 — NSR
III:5 36 — NSR
AD  antiarrhythmic drug; AF  atrial fibrillation; EF  ejection fraction; LA  left atrial; LVH f the disease. Consequently, the identification of well- aefined endophenotypes that cosegregate with AF has been
roposed to aid gene mapping (14). An endophenotype
hould not only cosegregate with the condition but also be
resent in an individual whether or not AF is present.
lthough it is possible that as the left atrial size increases
econdary to AF, the P-wave duration may lengthen, in our
tudy there was no uniform increase in left atrial size despite
rolongation of the SA P-wave duration in individuals
arrying the AF haplotype. In fact, the 1 individual with the
F haplotype (IV:1) but no documented history or symp-
oms of AF had a normal left atrial size. Therefore, in this
tudy, we showed that not only individuals with AF but also
hose who do not carry the AF haplotype could be identified
y SA ECG.
Abnormalities of the P-wave, such as increased duration
nd right and left atrial hypertrophy, are associated with an
ncreased incidence of AF (34). In our kindred, strikingly
s Echocardiography
Signal-Averaged
P-Wave (ms)
LA Size
(mm) EF Therapy
Normal — 45 0.60 Rate control
NA — NA NA Rate control
Normal 190 46 0.55 AAD
LVH 189 44 0.60 AAD
Normal 200 40 0.60 Rate control
LVH 180 42 0.55 AAD
Normal 210 NA 0.65 Rate control
Normal 250 38 0.65 NA
Normal 198 44 0.65 AAD
Normal 210 39 0.65 NA
Normal 112 36 0.60 —
Normal 104 34 0.60 —
Normal 108 38 0.55 —
Normal 107 40 0.60 —
Normal 112 38 0.50 —
Normal 141 36 0.55 —
Normal 105 37 0.55 —
Normal 117 36 0.50 —
Normal 118 38 0.60 —
LVH 134 40 0.65 —
Normal 140 39 0.55 —
Normal 110 36 0.65 —
Normal 125 40 0.60 —
Normal 118 38 0.55 —
Normal 120 36 0.60 —
Normal 105 38 0.60 —
Normal 110 38 0.60 —
tricular hypertrophy; NA  not available; NSR  normal sinus rhythm.ymptom
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
left venbnormal P-wave durations occurred in the absence of other
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Prolonged P-Wave and Familial AF March 18, 2008:1083–9athology. The routine ECG may, however, not identify
any other P-wave abnormalities that are risk factors for
F and are seen during intracardiac recording after pro-
rammed stimulation. These abnormalities not only reflect
tructural abnormalities of the atria but also alterations in
lectrical properties, the most important of which are
ntra-atrial and interatrial conduction abnormalities and
bnormalities of refractoriness throughout the atria. Because
he SA P-wave ECG is able to record low-level electrical
ignals, more precise measurements of duration and ampli-
ude of the P-wave can be made. Furthermore, SA P-wave
uration has been shown, in retrospective and prospective
tudies, to be able to discriminate between those at risk and
hose without risk of developing AF (35,36).
Figure 3 Representative Tracings of
Signal-Averaged P-Wave Duration
This patient (II:13) had no history or symptoms of AF, did not carry the AF hap-
lotype, and had a normal P-wave duration (top). A patient (II:20) with AF and
the disease haplotype who had prolonged SA P-wave duration (bottom). AF 
atrial fibrillation.
inkage in Family VAF-1 to Markers at 5p15
Table 2 Linkage in Family VAF-1 to Markers at 5p15
Marker
Recombination Fraction (theta)
0.00 0.05 0.10 0.20 0.30 0.40
D5S2088 0.68 0.42 0.12 0.28 0.49 0.40
D5S406 0.72 0.62 0.40 0.03 0.19 0.12
D5S2054 3.62* 3.08 2.97 2.10 1.58 0.98
D5S635 2.64 2.55 2.11 1.78 1.12 0.48
D5S807 0.26 0.08 0.00 0.29 0.39 0.58
D5S1486 0.08 0.26 0.24 0.28 0.32 0.16Maximum 2-point LOD score.
LOD  logarithm of the odds; VAF  Vanderbilt atrial fibrillation.onclusions
ur study showed that in this kindred, SA P-wave duration
as able to identify affected individuals and carriers of the
F haplotype. However, validation studies will need to be
erformed in additional cohorts before it can be concluded
hat it is a useful endophenotype for genetic studies of AF.
eprint requests and correspondence: Dr. Dawood Darbar,
ivision of Cardiovascular Medicine, Vanderbilt University
chool of Medicine, Room 1285A MRB IV, Nashville, Tennessee
7323-6602. E-mail: dawood.darbar@vanderbilt.edu.
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